Keywords: lilly, maintains, cost-effectiveness, zyprexa, drug, major, eli

Lilly maintains cost-effectiveness of Zyprexa

Article | 11 December 2006

Print This

US drug major Eli Lilly has commented on data from the cost-effectiveness analysis of the CATIE study. The firm noted ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in